Freidin Aaron sold $672K of GRAL
Freidin Aaron (Chief Financial Officer) sold 7,900 shares of GRAIL, Inc. (GRAL) at $85.01 ($0.67M total) on 2026-08-27 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction represents a modest reduction in insider ownership, unlikely to shift valuation dramatically.
Market read
Primary relevance to GRAL shareholders; limited broader market effect.
What to watch
Potential upcoming data releases or financing activities could contextualize the sale.
Background
Form 4 filings disclose insider transactions; CFO sales are monitored for material signals.
Ticker impact
CFO Aaron Freidin sold 7,900 shares for $671,579 via a 10b5-1 plan on 2026-08-27.
Potential short-term dip of 1‑2% as market digests insider sale.
Sale size is modest relative to holdings (≈3% of post‑sale position) and executed under a pre‑arranged plan, limiting strong inference.
Market effects
Minimal impact on the broader biotech sector; insider sales are routine.
U.S. market only; no regional ripple.
Low; limited to GRAL investors.
Counterpoint
The sale may be purely procedural under the 10b5‑1 plan, not indicative of negative outlook.
Key entities
- CompanyGRAIL, Inc.
US‑listed biotech firm developing early cancer detection tests.
- ExecutiveAaron Freidin
Chief Financial Officer of GRAIL.
